TNFSF11 and neoplasm: The 100 and 200 μg doses of the anti‐RANKL/PD‐1 BsAb significantly reduced established s.c. tumor growth of both 3LL and CT26 compared with cIg, anti‐PD‐1 monotherapy or anti‐RANKL monotherapy (****P < 0.0001 for comparison of BsAb to cIg, anti‐PD‐1 or anti‐RANKL treatment groups in both 3LL and CT26 models).